Skip to main content
NewslettersWatchlist

Ironwood Pharmaceuti(IRWD-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low4.10
Day High4.41
Open:4.30
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
Barchart
Chart of the Day: Ironwood Pharma - Gastrointestinal Products
Motley Fool
Down 7% in 2023, This Struggling Growth Stock Could Soon Make a Turnaround
Motley Fool
Why Ironwood Pharmaceuticals Stock Bumped Higher Today
Motley Fool
Why Shares of VectivBio Holding Are Up Today
Business Wire
Ironwood Presents New Data on Potential of Linaclotide for Functional Constipation in Children and Adolescents Ages 6-17 Years-Old at Digestive Disease Week® 2023
Business Wire
Ironwood Pharmaceuticals Reports First Quarter 2023 Results; Maintains Full Year 2023 Financial Guidance
Business Wire
Ironwood to Present New Data at Digestive Disease Week® 2023 Demonstrating Potential of Linaclotide for Functional Constipation in Children and Adolescents Ages 6-17 Years-Old
Business Wire
Ironwood Pharmaceuticals to Host First Quarter 2023 Investor Update Call
Business Wire
Ironwood Pharmaceuticals to Participate in Upcoming Investor Conferences
Business Wire
Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Results
Business Wire
Ironwood Pharmaceuticals Announces FDA Filing Acceptance and Priority Review of Supplemental New Drug Application for LINZESS® (linaclotide) for Functional Constipation in Children and Adolescents Ages 6-17 Years-Old
Motley Fool
3 No-Brainer Stocks to Buy Right Now for Less Than $25
Business Wire
Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2022 Investor Update Call
Business Wire
Ironwood Pharmaceuticals Provides Update on FY 2022 Financial Guidance and Announces FY 2023 Financial Guidance
Business Wire
Ironwood Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference
Business Wire
Ironwood Pharmaceuticals to Participate in the Piper Sandler 34th Annual Healthcare Conference
Business Wire
Ironwood Pharmaceuticals Reports Strong Third Quarter 2022 Results; Maintains Full Year 2022 Financial Guidance
Business Wire
Ironwood Pharmaceuticals to Host Third Quarter 2022 Investor Update Call
Business Wire
Ironwood Pharmaceuticals Reports Positive Topline Data from Phase III Trial of LINZESS® (linaclotide) in Pediatric Patients Aged 6-17 with Functional Constipation
Business Wire
Ironwood Pharmaceuticals to Present at the 2022 Wells Fargo Healthcare Conference
Business Wire
Ironwood Pharmaceuticals Reports Second Quarter 2022 Results; Maintains Full Year Guidance Due to Continued Strength of LINZESS® Prescription Demand
Business Wire
Ironwood Pharmaceuticals to Host Second Quarter 2022 Investor Update Call

Profile

Ironwood Pharmaceuticals, Inc. focuses on the development and commercialization of treatments primarily addressing gastrointestinal diseases. Linzess was launched in collaboration with Allergan for patients suffering from irritable bowel syndrome (IBS-C; 290 mcg) with constipation or chronic idiopathic constipation. Ironwood and AbbVie co-develop & co-commercialize Linzess in all other territories world wide. Linzess is marketed by Allergan for IBS-C in Europe and Canada under the brand name Constella. The company receives royalties on sales of Constella in Europe and Canada from AbbVie. In Japan, it has partnered with Astellas Pharma for the development and commercialization of Linzess and with AstraZeneca in China, Hong Kong & Macau. Linzess received approval for IBS-C indication in Japan for chronic constipation and in China for IBS-C. The company completed the spin-off of its soluble guanylate cyclase segment into a separate, publicly traded company, Cyclerion Therapeutics.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.